If mgmt is worried about sec, it's there own doing. there is another lawsuit in play regarding mgmt self dealing. this one has merit imo because mgmt has done nothing but self dealing. maybe that's why the next grant of options have been delayed. the fact that the bod remains incestuous and lacking any real biotech experience is alarming. mgmt has put a poison pill or giant stink bug around the company with the bod. my guess is the current bod makeup is a major red flag for institutional investors.